CDER New Drug Reviews Are At 80%-90% Of User Fee Goals, Jenkins Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Center for Drug Evaluation and Research's performance in reviewing applications for new drugs and biologics within the timelines specified by the Prescription Drug User Fee Act has slipped to 80 percent to 90 percent